Alex Braun
Head of Investor Relations
Replay available
Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) Q1 2026 earnings conference call, held 2026-05-12. Replay captured from the company's public earnings webcast.

Head of Investor Relations
CFO and Chief Business Officer
Analyst, Cantor Fitzgerald
President and Chief Development Officer
Analyst, Citi
Chief Medical Officer
Analyst, CFO
Analyst, Bank of America
Analyst, BTIG
Analyst, Lucid Capital Markets
Good day and thank you for standing by. Welcome to the Acumen Pharma first quarter 2026 conference call and webcast. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 11 again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Alex Braun, Head of Investor Relations. Please go ahead. Thanks, Didi. Good morning and welcome to the Acumen Conference Call to discuss our business update and financial results for the quarter ended March 31st, 2026. With me today are Dan O'Connell, our Chief Executive Officer, and Matt Zuga, our CFO and Chief Business Officer. They will have brief prepared remarks, and then we'll open the call for questions. Joining for the Q&A session, we also have Dr. Jim Doherty, our President and Chief Development Officer, and Dr. Eric Siemers, our Chief Medical Officer. Before we begin, we encourage listeners to go to the Investors section of the Acumen website to find our press release issued this morning that we'll discuss today. Please note that during today's conference call, we may make forward-looking statements within the meaning of the federal securities laws, including statements concerning our financial outlook and expected business plans. Please see slide two of our corporate presentation, our press release issued this morning, and our most recent annual and quarterly reports filed with the SEC for important risk factors that could cause our actual results to differ material...